CN114058515B - 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 - Google Patents
一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 Download PDFInfo
- Publication number
- CN114058515B CN114058515B CN202111192566.5A CN202111192566A CN114058515B CN 114058515 B CN114058515 B CN 114058515B CN 202111192566 A CN202111192566 A CN 202111192566A CN 114058515 B CN114058515 B CN 114058515B
- Authority
- CN
- China
- Prior art keywords
- nannochloropsis
- engineering strain
- cholesterol
- strain
- methylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000224474 Nannochloropsis Species 0.000 title claims abstract description 41
- INDVLXYUCBVVKW-RNWIMVDMSA-N 24-Methylene cholesterol Natural products O[C@@H]1CC=2[C@@](C)([C@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCC(C(C)C)=C)C)CC4)CC3)CC=2)CC1 INDVLXYUCBVVKW-RNWIMVDMSA-N 0.000 title claims abstract description 15
- INDVLXYUCBVVKW-PXBBAZSNSA-N 24-methylenecholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(=C)C(C)C)[C@@]1(C)CC2 INDVLXYUCBVVKW-PXBBAZSNSA-N 0.000 title claims abstract description 15
- INDVLXYUCBVVKW-UHFFFAOYSA-N Methylencholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=C)C(C)C)C1(C)CC2 INDVLXYUCBVVKW-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 239000013535 sea water Substances 0.000 title abstract description 5
- 229940109850 royal jelly Drugs 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title description 5
- 239000004480 active ingredient Substances 0.000 title description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 34
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 15
- 108091033409 CRISPR Proteins 0.000 claims abstract description 8
- 101100063431 Arabidopsis thaliana DIM gene Proteins 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 5
- 238000005516 engineering process Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 10
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000012452 mother liquor Substances 0.000 claims description 8
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 150000003432 sterols Chemical class 0.000 claims description 7
- 235000003702 sterols Nutrition 0.000 claims description 7
- 239000012984 antibiotic solution Substances 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 239000011573 trace mineral Substances 0.000 claims description 5
- 235000013619 trace mineral Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims description 4
- 229960004261 cefotaxime Drugs 0.000 claims description 4
- 238000012136 culture method Methods 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 4
- 235000010344 sodium nitrate Nutrition 0.000 claims description 4
- 239000004317 sodium nitrate Substances 0.000 claims description 4
- 229960001931 ampicillin sodium Drugs 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000011550 stock solution Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 235000001497 healthy food Nutrition 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 2
- 208000005392 Spasm Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 229910002092 carbon dioxide Inorganic materials 0.000 abstract 1
- 239000001569 carbon dioxide Substances 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 241000195493 Cryptophyta Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000004300 dark adaptation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- SGNBVLSWZMBQTH-QGOUJLTDSA-N (3s,8s,9s,10r,13r,14s,17r)-17-[(2r)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-QGOUJLTDSA-N 0.000 description 1
- CPQUIAPJXYFMHN-UHFFFAOYSA-N 24-methylcholesterol Natural products C1CC2=CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 CPQUIAPJXYFMHN-UHFFFAOYSA-N 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003225 biodiesel Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- -1 steroid compound Chemical class 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/12—Unicellular algae; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P33/00—Preparation of steroids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/20—Reduction of greenhouse gas [GHG] emissions in agriculture, e.g. CO2
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Birds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及基因工程技术领域,特别涉及一种微拟球藻工程株及其制备方法和应用。该工程株为敲除DWARF1(DWF1)基因的微拟球藻。本发明利用CRISPR CAS9技术,在不引入任何外源分子标签的前体下,构建出DWF1基因的敲除株,得到胆固醇含量显著降低、24‑亚甲基胆固醇含量显著提高的工程株,其遗传性状稳定。4‑亚甲基胆固醇是蜂王浆主成分,具降血压、抗心律失常、血管解痉等活性。若将此工程株产业化生产,有助于填补高24‑亚甲基胆固醇微藻这一领域的空白,实现利用海洋微拟球藻开发高24‑亚甲基胆固醇、高二十碳五烯酸、低胆固醇的健康食品,并为利用海水和二氧化碳工业化生产人造蜂王浆提供理论依据。
Description
技术领域
本发明涉及基因工程技术领域,特别涉及一种微拟球藻工程株及其制备方法和应用。
背景技术
微拟球藻(Nannocloropsis oceanica)是一种光合自养的圆球状的单细胞生物,在缺氮胁迫条件下能产生大量的脂质积累,累积量高达其生物量干重的60%,故常用作生物柴油的潜在替代品。除此之外,它也能用作一系列高附加值产品的开发,如食品、饲料添加剂、色素、化妆品、药品等。而其代谢产物如叶绿素、甾醇、类胡萝卜素和一些植物激素,决定了对生长或产生有价值的化学物质至关重要的细胞特性。微拟球藻富含油脂,且有特别高含量的PUFA(polyunsaturated fatty acid,多不饱和脂肪酸),如EPA(eicosapentaenoic acid,二十碳五烯酸),它在功能食品、功能饵料等方面具有巨大的经济价值及广阔的应用前景。
胆固醇是构成人体组织细胞所不可或缺的重要组成物质,它不仅参与细胞膜的形成,而且是合成维生素D、胆汁酸及甾体激素的重要原料。但当人体血清胆固醇含量过高时,易导致高胆固醇血症的发生,对人体产生不利的影响。现代研究发现,动脉粥样硬化性、心脑血管疾病及冠心病等的发生与高胆固醇血症有密切的联系。因此,降低血清中过多的胆固醇含量对人身体健康是有利的。微拟球藻因其富含EPA,被广泛用于功能食品和功能饵料开发,但却因含有高的胆固醇而饱受诟病。
微拟球藻中胆固醇的合成前体是24-亚甲基胆固醇(Lu et al.,2014 Regulationof the cholesterol biosynthetic pathway and its integration with fattyacidbiosynthesis inthe oleaginous microalgaNannochloropsis oceanica)。24-亚甲基胆固醇是蜂王浆主要的甾体化合物,具有降血压、降低血清胆固醇、减慢心率、抗心律失常、血管解痉等多种生物活性(Chakrabarti et al.,2020 Evaluating effects of acritical micronutrient(24-methylenecholesterol)on honey bee physiology)。
目前,还未见针对胆固醇和24-亚甲基胆固醇含量进行改造的微拟球藻工程株。
发明内容
有鉴于此,本发明提供了一种微拟球藻工程株及其制备方法和应用。本发明获得一株低胆固醇、高24-亚甲基胆固醇工程微拟球藻细胞,其胆固醇含量下降98.7%,24-亚甲基胆固醇含量提高了222倍,且性状可稳定遗传,可用于产业化生产高多不饱和脂肪酸、高24-亚甲基胆固醇、低胆固醇的功能食品和水产饵料,为绿色健康产业服务。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种微拟球藻工程株,其为敲除DWF1基因的微拟球藻。
本发明还提供了该微拟球藻工程株的制备方法,采用CRISPR/Cas9技术将微拟球藻中的DWF1基因敲除。
本发明还提供了该微拟球藻工程株的培养方法,将微拟球藻工程株接种于平板培养基中进行培养;平板培养基配方为:
优选地,平板培养基配方为:
作为优选,营养液母液的配方为:
硝酸钠 30~50g
一水合磷酸二氢钠 1~5g
水 补足至200mL。
优选地,营养液母液的配方为:
硝酸钠 40g
一水合磷酸二氢钠 2.66g
水 补足至200mL。
作为优选,维生素母液的配方为:
优选地,维生素母液的配方为:
作为优选,微量元素溶液的配方为:
优选地,微量元素溶液的配方为:
作为优选,抗生素溶液的配方为:
氨苄青霉素钠 0.5~2mg
头孢氨噻肟 0.5~2mg
水 补足至10mL。
优选地,抗生素溶液的配方为:
氨苄青霉素钠 1mg
头孢氨噻肟 1mg
水 补足至10mL。
本发明还提供了一种诱导微拟球藻工程株生产甾醇的方法,对上述微拟球藻工程株进行高光胁迫诱导培养。
作为优选,高光胁迫诱导培养的条件为:将经过验证后的转化子与野生型均接种至PBR中培养至对数生长期,即OD750=2.0-3.5,然后转接至含120mLf/2培养基的250mL三角瓶中,每组设置三个平行,过夜暗适应后,置于光强为200μmol·photons·m-2·s-1,25℃,24h光照的光照培养箱中,于第10天离心收集藻液,将样品冷冻真空干燥后,用于后续GC-MS的分析。
本发明还提供了该微拟球藻工程株在制备低胆固醇、高24-亚甲基胆固醇功能食品或水产饵料中的应用。
本发明具有的技术效果如下:
目前还未见针对DWF1基因在微拟球藻中的研究,传统遗传工程策略往往引入外源抗性标签,会引发公众对转基因食品的顾虑。本发明利用CRISPR CAS9技术,在不引入任何外源分子标签的前体下,构建出微拟球藻DWF1基因的敲除株,得到胆固醇含量显著降低(从近70%下降至1.55%以下)、24-亚甲基胆固醇含量显著提高(从0.29%提高至超过60%,以提高最明显的dwf1-6为例)的工程株,这一工程株遗传性状稳定,若将此工程株进行产业化生产,有助于填补低胆固醇、高24-亚甲基胆固醇微藻这一领域上的空白,为将微拟球藻用于开发低胆固醇含量的健康食品的生产应用提供理论依据。将此工程株应用于开发成食品、保健品或特殊医学配方食品等,可以满足人民对于健康的需求。
附图说明
图1转化子验证;
图2野生型微拟球藻的甾醇峰图;
图3 dwarf1(即dwf1)敲除株的甾醇峰图;
图4野生型与突变体的甾醇峰图叠加图。
具体实施方式
本发明公开了一种微拟球藻工程株及其制备方法和应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
本发明中所用试剂或仪器均可由市场购得。
下面结合实施例,进一步阐述本发明:
实施例1
1、平板培养基配制如下:
将10g琼脂粉溶入1L配制的人工海水中,配制成1%的琼脂液固体培养基中,放入灭菌锅中121℃,灭菌20min。灭菌完成后趁热在超净工作台上用移液器吸取5mL营养液母液、500μL微量元素溶液、1mL抗生素溶液以及3μL100mg/mL的潮霉素B加入琼脂液中,摇匀,倒平板。(注:营养液母液及微量元素溶液均需要提前灭菌,121℃,20min;维生素母液和抗生素溶液均需要预先0.22μm膜过滤除菌)
表1营养液母液配方(200mL)
物料名称 | 分子式 | 级别 | 称量量(g) |
硝酸钠 | NaNO3 | AR | 40 |
一水合磷酸二氢钠 | NaH2PO4·H2O | AR | 2.66 |
表2维生素母液配方(100mL)
物料名称 | 分子式 | 级别 | 称量量(mg) |
维生素B12 | VitaminB12 | AR | 1 |
生物素 | Biotin | AR | 1 |
维生素B1 | VitaminB1 | AR | 20 |
表3微量元素溶液母液配方(200mL)
物料名称 | 分子式 | 级别 | 称量量(mg) |
乙二胺四乙酸二钠 | Na2EDTA | AR | 874 |
六水合氯化铁 | FeCl3.6H2O | AR | 730 |
五水硫酸铜 | CuSO4·5H2O | AR | 3.92 |
七水硫酸锌 | ZnSO4·7H2O | AR | 8.8 |
六水氯化钴 | CoCl2·6H2O | AR | 2.184 |
四水氯化锰 | MnCl2·4H2O | AR | 72 |
二水钼酸钠 | Na2MoO4·2H2O | AR | 2.52 |
表4抗生素溶液配方(10mL)
物料名称 | 分子式 | 级别 | 称量量(mg) |
氨苄青霉素钠 | C16H18N3NaO4S | AR | 1 |
头孢氨噻肟 | C16H16N5O7S2Na | AR | 1 |
2、利用CRISPR CAS9技术,构建出微拟球藻DWARF1基因的敲除株。
需敲除的微拟球藻DWARF1基因序列为:
ATGCCGCAACCAAGTCTGAAGTCCTTCGCCTCCAAAGGCAAAGGGAAGCCCCAGCGAGAGGAGAACTTTTTTGAGTATATGATTACTCACCACCGATGGGTCTTTTGCGTCTTCTTGCTAATGCCACTGTCGCTTGCGTTTGATATTGTCCTCTATGTCCGCAATAGCGTCCAGTTTTATCTCCGAAATTGGGCACCCAAGCAACACGAGGCCAAAGTGGAGGAGATCAAGAAGCAGATTTTAGAGTGGGCTAAGCATGACGGCAAGAACAAGCTGTGCACCGCTCGCCCGGGTTGGCAGACCATGTCCCTGCGTGTCGGAAAATACAAGAAGACATTCCGTAAGGTCAAGCTGGATCTACATGACATCCTCTCCATCACCACCACCGGTCAATCTCCCTCCGTTTGCGTCGAGCCCCTCGTCACCATGGGGCAGCTGACTGCCGCCCTCCTCCCCGTTGGTTGGACCGTGCCTGTCTTACCTGAACTAGACGACTTGACTATCGGGGGTTTGATTGCTGGAGTGGGTGTGGAAAGCTCTAGTCATATTTACGGGCTCTTCCAACACATTTGCATGGAGTTTGAGGTGGCATTGGCGGATGGCTCGGTCGTCTTTTGCAGCCCTGAGAAGAATGCCGAGTTGTTTTACAACTTGCCTTGGTCGCATGGCACGCTTGGCTTTTTGTTATCCGCTACAATTAGGATCATCCCTGCGAAACAATACGTGAAATTAGAGTACTTTGCGTTTACCAATGGCGGGAAAGCCCTGGAGATGTTTGAGAGGGAGAGCAGGAAAGGCGTGAACCGTCCTCCGCTCGCTGGGACGCAAGTCGCGTATGCGGCCGCTGCGGACTTGAAAAAAAGGATGGAGGGAGGGGTGACTGGGAAGGGGGAGGGCGATGAGGGGTCCTCGCCTGTAGGGGGAGGGAGGGAGGACGCGGCGGACTATGTGGAGGCGCTTGCGTATAGCCGAGAGCATGTAGTGGTGATGTTGGGGACGATGGTGGATACGCCTGAGGGGGGTAAGGAGGCAGGGAAGGTAAACGCGTTGGGCAAGTTTTGGAAGCCGTGGTTTTTCAAGCACGTGGAGGGGTTTCTGGTCAAGGGAGGGAAGGAGGGAGAGAGGGTGGCCGTGGAGTATGTGCCATTGCGGCATTACTACCACCGGCACAGCAAGAGTTTGTTCTGGGAGATTCAGGACATCATTCCCTTTGGGAATAACGTGGTGTTCCGGTACCTGTTTGGGTGGATGATGCCTCCGCGCATTTCGCTTCTGAAACTGACTCAAACGGAAGCTTTGCGGAAGCTGTACGAGGAGCATCACGTGGTACAGGACATGCTGGTACCCGTCAAGGACCTGGGAGAGGGCTTGGATGTGTTCGAGGAGGTGTTCGGCGTGTACCCGCTCTGGCTGTGCCCCATGCGCATCCCCAAGAATCCGGATTATGCCAAGTTTGGCGGGTTTGTCAAGCCGTTGGAAGGGGGGAAAGACGAGATGTTTGTGGACGTGGGCGCGTACGGCAACCCAAGCATGGAGGGATTTAATGCCCGAGAGGCGTGTCGAAAGGCAGAGGACTGGGTGCGGGCCAAGAAAGGTTACCAAATGATGTACGCCGACTCCTTCATGACGCGAGAAGAGTTCCGGGAGATGTTTGATCACTCCAAGTACGACGAGCTCAGGCGGCGGATGGATCTATGCCTGCAGGCGTTTCCTGAGGTGTACGATAAGGTCAGCAAGGCTGCACGGGTCTAG
电穿孔转化参照Wang等(Wang et al.,Genome editing ofmodel oleaginousmicroalgaeNannochloropsis spp.by CRISPR/Cas9)。基因敲除参照Lu等(Lu et al.,Roleof an ancient light-harvesting protein of PSI in light absorption andphotoprotection)。转化后的藻液涂于含300μg/L潮霉素的f/2平板中,挑选至液体培养基(步骤1中配制的平板培养基不加琼脂即为液体培养基)中进行培养,平板培养温度为25℃,光照强度为50μmol·photons·m-2·s-1。培养21天。
3、单克隆培养
待平板上长出肉眼可见的较大的单克隆时,挑取若干单克隆至含f/2液体培养基的50mL三角瓶中。置于培养箱中25℃,50μmol·photons·m-2·s-1下培养10-15天。
4、PCR验证
待生长至肉眼可见绿色时取藻液进行藻液PCR验证,用XD-001F与XD-001R引物对进行扩增,PCR产物大小约为660bp。
XD-001F:TGGATCAGCAAGACGAAGACCT
XD-001R:CGGAGATAAAACTGGACGCTATTG
并将PCR产物送测序,用基因组序列进行blastn比对,确认是否在PAM区发生移码突变,使得该基因失效。验证的PCR电泳图见图1。
实验得到了三株转化子,分别命名为dwf1-1、dwf1-6、dwf1-7。
5、高光胁迫处理
将经过验证后的转化子与野生型均接种至PBR中培养至对数生长期,即OD750=2.0-3.5,然后转接至含120mLf/2培养基的250mL三角瓶中,每组设置三个平行,过夜暗适应后,置于光强为200μmol·photons·m-2·s-1,25℃,24h光照的光照培养箱中,于第10天离心收集藻液,将样品冷冻真空干燥后,用于后续GC-MS的分析。峰图见图2、图3、图4。(注:无论野生型还是突变体,均选用了三个生物学重复中差异最大的一个用作展示说明。)
6、GC-MS分析
GC-MS分析技术参数:流量1mL/min,起始温度170℃,持续1min,然后以20℃/min上升到280℃,停留至少15min,离子源温度为150℃,进样量1μL,柱箱温度为170℃。
表5微拟球藻在高光胁迫处理下的GC/MS甾醇数据分析
为了评价不同处理的效果,每个样品在上述条件下建立三个生物重复。采用单因素方差分析评价各处理的差异,然后进行p值检验。数据以平均值±标准差(n≥3)表示。p值<0.05时,差异被认为是显著的。
由表可见,突变体的胆固醇相对含量与野生型相比,显著降低。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 海南大学
<120> 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法
<130> MP21025541
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1752
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atgccgcaac caagtctgaa gtccttcgcc tccaaaggca aagggaagcc ccagcgagag 60
gagaactttt ttgagtatat gattactcac caccgatggg tcttttgcgt cttcttgcta 120
atgccactgt cgcttgcgtt tgatattgtc ctctatgtcc gcaatagcgt ccagttttat 180
ctccgaaatt gggcacccaa gcaacacgag gccaaagtgg aggagatcaa gaagcagatt 240
ttagagtggg ctaagcatga cggcaagaac aagctgtgca ccgctcgccc gggttggcag 300
accatgtccc tgcgtgtcgg aaaatacaag aagacattcc gtaaggtcaa gctggatcta 360
catgacatcc tctccatcac caccaccggt caatctccct ccgtttgcgt cgagcccctc 420
gtcaccatgg ggcagctgac tgccgccctc ctccccgttg gttggaccgt gcctgtctta 480
cctgaactag acgacttgac tatcgggggt ttgattgctg gagtgggtgt ggaaagctct 540
agtcatattt acgggctctt ccaacacatt tgcatggagt ttgaggtggc attggcggat 600
ggctcggtcg tcttttgcag ccctgagaag aatgccgagt tgttttacaa cttgccttgg 660
tcgcatggca cgcttggctt tttgttatcc gctacaatta ggatcatccc tgcgaaacaa 720
tacgtgaaat tagagtactt tgcgtttacc aatggcggga aagccctgga gatgtttgag 780
agggagagca ggaaaggcgt gaaccgtcct ccgctcgctg ggacgcaagt cgcgtatgcg 840
gccgctgcgg acttgaaaaa aaggatggag ggaggggtga ctgggaaggg ggagggcgat 900
gaggggtcct cgcctgtagg gggagggagg gaggacgcgg cggactatgt ggaggcgctt 960
gcgtatagcc gagagcatgt agtggtgatg ttggggacga tggtggatac gcctgagggg 1020
ggtaaggagg cagggaaggt aaacgcgttg ggcaagtttt ggaagccgtg gtttttcaag 1080
cacgtggagg ggtttctggt caagggaggg aaggagggag agagggtggc cgtggagtat 1140
gtgccattgc ggcattacta ccaccggcac agcaagagtt tgttctggga gattcaggac 1200
atcattccct ttgggaataa cgtggtgttc cggtacctgt ttgggtggat gatgcctccg 1260
cgcatttcgc ttctgaaact gactcaaacg gaagctttgc ggaagctgta cgaggagcat 1320
cacgtggtac aggacatgct ggtacccgtc aaggacctgg gagagggctt ggatgtgttc 1380
gaggaggtgt tcggcgtgta cccgctctgg ctgtgcccca tgcgcatccc caagaatccg 1440
gattatgcca agtttggcgg gtttgtcaag ccgttggaag gggggaaaga cgagatgttt 1500
gtggacgtgg gcgcgtacgg caacccaagc atggagggat ttaatgcccg agaggcgtgt 1560
cgaaaggcag aggactgggt gcgggccaag aaaggttacc aaatgatgta cgccgactcc 1620
ttcatgacgc gagaagagtt ccgggagatg tttgatcact ccaagtacga cgagctcagg 1680
cggcggatgg atctatgcct gcaggcgttt cctgaggtgt acgataaggt cagcaaggct 1740
gcacgggtct ag 1752
<210> 2
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
tggatcagca agacgaagac ct 22
<210> 3
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
cggagataaa actggacgct attg 24
Claims (10)
1.一种微拟球藻工程株,其特征在于,其为敲除DWF1基因的微拟球藻;
所述DWARF1基因序列为:
ATGCCGCAACCAAGTCTGAAGTCCTTCGCCTCCAAAGGCAAAGGGAAGCCCCAGCGAGAGGAGAACTTTTTTGAGTATATGATTACTCACCACCGATGGGTCTTTTGCGTCTTCTTGCTAATGCCACTGTCGCTTGCGTTTGATATTGTCCTCTATGTCCGCAATAGCGTCCAGTTTTATCTCCGAAATTGGGCACCCAAGCAACACGAGGCCAAAGTGGAGGAGATCAAGAAGCAGATTTTAGAGTGGGCTAAGCATGACGGCAAGAACAAGCTGTGCACCGCTCGCCCGGGTTGGCAGACCATGTCCCTGCGTGTCGGAAAATACAAGAAGACATTCCGTAAGGTCAAGCTGGATCTACATGACATCCTCTCCATCACCACCACCGGTCAATCTCCCTCCGTTTGCGTCGAGCCCCTCGTCACCATGGGGCAGCTGACTGCCGCCCTCCTCCCCGTTGGTTGGACCGTGCCTGTCTTACCTGAACTAGACGACTTGACTATCGGGGGTTTGATTGCTGGAGTGGGTGTGGAAAGCTCTAGTCATATTTACGGGCTCTTCCAACACATTTGCATGGAGTTTGAGGTGGCATTGGCGGATGGCTCGGTCGTCTTTTGCAGCCCTGAGAAGAATGCCGAGTTGTTTTACAACTTGCCTTGGTCGCATGGCACGCTTGGCTTTTTGTTATCCGCTACAATTAGGATCATCCCTGCGAAACAATACGTGAAATTAGAGTACTTTGCGTTTACCAATGGCGGGAAAGCCCTGGAGATGTTTGAGAGGGAGAGCAGGAAAGGCGTGAACCGTCCTCCGCTCGCTGGGACGCAAGTCGCGTATGCGGCCGCTGCGGACTTGAAAAAAAGGATGGAGGGAGGGGTGACTGGGAAGGGGGAGGGCGATGAGGGGTCCTCGCCTGTAGGGGGAGGGAGGGAGGACGCGGCGGACTATGTGGAGGCGCTTGCGTATAGCCGAGAGCATGTAGTGGTGATGTTGGGGACGATGGTGGATACGCCTGAGGGGGGTAAGGAGGCAGGGAAGGTAAACGCGTTGGGCAAGTTTTGGAAGCCGTGGTTTTTCAAGCACGTGGAGGGGTTTCTGGTCAAGGGAGGGAAGGAGGGAGAGAGGGTGGCCGTGGAGTATGTGCCATTGCGGCATTACTACCACCGGCACAGCAAGAGTTTGTTCTGGGAGATTCAGGACATCATTCCCTTTGGGAATAACGTGGTGTTCCGGTACCTGTTTGGGTGGATGATGCCTCCGCGCATTTCGCTTCTGAAACTGACTCAAACGGAAGCTTTGCGGAAGCTGTACGAGGAGCATCACGTGGTACAGGACATGCTGGTACCCGTCAAGGACCTGGGAGAGGGCTTGGATGTGTTCGAGGAGGTGTTCGGCGTGTACCCGCTCTGGCTGTGCCCCATGCGCATCCCCAAGAATCCGGATTATGCCAAGTTTGGCGGGTTTGTCAAGCCGTTGGAAGGGGGGAAAGACGAGATGTTTGTGGACGTGGGCGCGTACGGCAACCCAAGCATGGAGGGATTTAATGCCCGAGAGGCGTGTCGAAAGGCAGAGGACTGGGTGCGGGCCAAGAAAGGTTACCAAATGATGTACGCCGACTCCTTCATGACGCGAGAAGAGTTCCGGGAGATGTTTGATCACTCCAAGTACGACGAGCTCAGGCGGCGGATGGATCTATGCCTGCAGGCGTTTCCTGAGGTGTACGATAAGGTCAGCAAGGCTGCACGGGTCTAG。
2.权利要求1所述微拟球藻工程株的制备方法,其特征在于,采用CRISPR/Cas9技术将微拟球藻中的DWF1基因敲除。
4.根据权利要求3所述的培养方法,其特征在于,所述营养液母液的配方为:
硝酸钠30~50g
一水合磷酸二氢钠1~5g
水补足至200mL。
7.根据权利要求3至6中任一项所述的培养方法,其特征在于,所述抗生素溶液的配方为:
氨苄青霉素钠 0.5~2mg
头孢氨噻肟 0.5~2mg
水 补足至10mL。
8.一种诱导微拟球藻工程株生产甾醇的方法,其特征在于,对权利要求1所述微拟球藻工程株进行高光胁迫诱导培养。
9.根据权利要求8所述的方法,其特征在于,所述高光胁迫诱导培养的条件为:200μmol·photons·m-2·s-1,25℃,24h光照。
10.权利要求1所述微拟球藻工程株在制备低胆固醇、高24-亚甲基胆固醇功能食品、保健品或水产饵料中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111192566.5A CN114058515B (zh) | 2021-10-13 | 2021-10-13 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
PCT/CN2021/139526 WO2023060761A1 (zh) | 2021-10-13 | 2021-12-20 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111192566.5A CN114058515B (zh) | 2021-10-13 | 2021-10-13 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114058515A CN114058515A (zh) | 2022-02-18 |
CN114058515B true CN114058515B (zh) | 2023-06-30 |
Family
ID=80234360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111192566.5A Active CN114058515B (zh) | 2021-10-13 | 2021-10-13 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114058515B (zh) |
WO (1) | WO2023060761A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114058515B (zh) * | 2021-10-13 | 2023-06-30 | 海南大学 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
CN115927436A (zh) * | 2022-11-28 | 2023-04-07 | 浙江大学 | 一种合成24-表麦角固醇真菌的构建方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104946535A (zh) * | 2014-03-26 | 2015-09-30 | 中国科学院青岛生物能源与过程研究所 | 一种可以调控微藻生长和其它功能的生长调节剂及其鉴定方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7151279B2 (ja) * | 2018-08-29 | 2022-10-12 | 味の素株式会社 | ステロールの製造法 |
CN114058515B (zh) * | 2021-10-13 | 2023-06-30 | 海南大学 | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 |
-
2021
- 2021-10-13 CN CN202111192566.5A patent/CN114058515B/zh active Active
- 2021-12-20 WO PCT/CN2021/139526 patent/WO2023060761A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104946535A (zh) * | 2014-03-26 | 2015-09-30 | 中国科学院青岛生物能源与过程研究所 | 一种可以调控微藻生长和其它功能的生长调节剂及其鉴定方法和应用 |
Non-Patent Citations (1)
Title |
---|
Regulation of the cholesterol biosynthetic pathway and its integration with fatty acid biosynthesis in the oleaginous microalga Nannochloropsis oceanica;Yandu Lu 等;Biotechnology for Biofuels;第7卷;第1-15页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023060761A1 (zh) | 2023-04-20 |
CN114058515A (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114058515B (zh) | 一种利用海水微拟球藻生产蜂王浆主效成分24-亚甲基胆固醇的方法 | |
US5244921A (en) | Eicosapentaenoic acids and methods for their production | |
JP6705754B2 (ja) | Dhaの製造のための塩化物及びナトリウムを含有しない培地中におけるオーランチオキトリウム属の微細藻類を培養する方法 | |
AU2016399463B2 (en) | Omega-7 fatty acid composition, methods of cultivation of Tribonema for production of composition and application of composition | |
CN105755088B (zh) | 诱导雨生红球藻生产虾青素的方法 | |
CN103882072B (zh) | 一种利用裂殖壶菌生产二十二碳六烯酸的方法 | |
CN110218661A (zh) | 一种热带假丝酵母菌及其应用、以及一种长链二元酸的生产方法 | |
Dashti et al. | Batch culture and repeated-batch culture of Cunninghamella bainieri 2A1 for lipid production as a comparative study | |
CN112481348A (zh) | 一种高产dha裂殖壶菌突变菌株的筛选方法 | |
KR100736150B1 (ko) | 소포자 배양 기술을 이용한 고추의 정상 배 생산 방법 | |
WO2010096382A1 (en) | Processes for the production of proteins containing selenium using yeast cells | |
CN101709297A (zh) | 一种花生四烯酸产生菌高山被孢霉的诱变筛选方法 | |
CN109022284A (zh) | 提高球等鞭金藻生物量以及dha产量的方法 | |
CN109022523A (zh) | 从球等鞭金藻中提取dha藻油和藻蛋白的工艺 | |
CN109825438B (zh) | 培养红藻门单细胞海洋微藻生产生物活性成分的方法 | |
CN104152503B (zh) | 一种提高异养下微藻脂肪酸产率的方法 | |
US5521090A (en) | L-ascorbic acid containing biomass of chlorella pyrenoidosa | |
CN114134045B (zh) | 一种同时高产维生素d3和二十碳五烯酸的微拟球藻工程株及其制备方法和应用 | |
US20240164418A1 (en) | Organic selenium enriched edible marine microalgal biomass | |
CN111349566B (zh) | 一株利用海水培养的魏氏藻及其用途 | |
CN108587913B (zh) | 一种具有高α-亚麻酸含量的栅藻、其培养方法及其应用 | |
CA2032648A1 (en) | Process for the production of polyunsaturated fatty acids | |
CN112481250A (zh) | 一种高产dha裂殖壶菌突变菌株的诱变育种方法 | |
CN112358970B (zh) | 拟微绿球藻及其应用 | |
JP6434268B2 (ja) | クロロフィルおよびカロテノイド高含有クロレラ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |